Y-Mabs Therapeutics Inc

NASDAQ:YMAB

26.40

-2.09 (-7.34%)

Market Cap (Intraday)	1.06B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$41.98 Million
Adjusted EPS	$0.34

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Y-mAbs Therapeutics, Inc. Stock, NASDAQ:YMAB

230 Park Avenue, Suite 3350, New York, New York 10169

United States of America

Phone: +1.646.885.8505

Number of Employees: 65

http://www.ymabs.com

Description

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.